click below
click below
Normal Size Small Size show me how
Autism
Uni of Notts, Neurobiology of Disease, year 2, topic 13
| Term | Definition |
|---|---|
| Core diagnostic domains of ASD | Deficits in two core domains: social impairment (atypical social behaviors) & speech communication discrepancy (disrupted verbal/non-verbal communication) + restricted repetitive & stereotypic behaviors |
| Spoken language delay in ASD | Manifests as heterogeneous delay in spoken language occurring in approximately 50% of autism spectrum disorder cases |
| Autism diagnostic classification under the DSM-V | Combines autistic disorder, Asperger's disorder, & pervasive developmental disorder-not otherwise specified (PDD-NOS), into a single umbrella diagnosis of Autism Spectrum Disorder |
| FDA-approved medications for autism | Only 2nd & 3rd generation antipsychotics (e.g., risperidone, aripiprazole); reduce irritability, aggression, & repetitive behaviors but don't treat underlying core social or communicative deficits |
| Prevalence & sex distribution of autism spectrum disorder | 1 in 68 children under 8 in the US; however, prevalence has risen to 1 in 31 children, roughly 3.4 to 5 times more common in males |
| Clinical utility of EEGs in autism | Detect clinical seizures & subclinical epileptiform activity (especially during sleep). Identifying & treating autism-related seizures can improve language regression, cognitive function, & aggressive behaviors |
| Chromosomal Copy Number Variations (CNVs) in autism | large sections of genomic DNA are deleted or duplicated. These often disrupt multiple genes critical for synaptic pathway development & neurodevelopment |
| Synaptic proteins Trio & SHANK3 in ASD | De novo or rare inherited mutations impact Trio & SHANK3 proteins within dendritic spines of glutamatergic neurons, leading to abnormal enhancement or reduction of glutamatergic synaptogenesis |
| Cortical minicolumn & whole-brain alterations in autism | Cortical minicolumns (basic anatomical microcircuits of the cerebral cortex) narrower, more numerous, or more tightly packed in ASD, altering local connectivity & disrupting the balance of excitation & inhibition. Brain slightly larger until adolescence |
| Cellular & molecular pathway changes | Variations in voltage-gated sodium channels alter baseline neuronal activity. Cellular changes also affect activity-dependent protein synthesis, cell adhesion molecules, & phospholipid homeostasis via ABCA transport channels |
| Role of the SHANK3 protein at the synapse | Acts as a scaffold to array post-synaptic receptors (NMDA-R, AMPA-R, mGluR). Dysfunctional SHANK3 can result in severely diminished or absent glutamatergic signaling in ASD |
| Neuroligins & excitatory-inhibitory balance | Post-synaptic cell adhesion molecules that bind neurexins, aligning glutamate or GABA receptors to guide synaptogenesis. Mutations disrupt GABA/glutamate balance, causing atypical, aberrant neural signaling |
| Impact of GABA signaling mutations in mice | Specific mutations elevate spontaneous inhibitory post-synaptic currents (IPSCs) without changing spontaneous EPSCs. The increased GABAergic signaling correlates directly with reduced social interaction behaviors |
| Neurexins in synaptic adhesion | Presynaptic membrane proteins that interact with exocytosis machinery & bind to postsynaptic neuroligins. They physically link across the synaptic cleft to structurally stabilize & maintain the synapse |
| Dopamine D2 receptor alterations in the striatum in autism | Post-mortem tissue from individuals with ASD shows a marked upregulation of dopamine D2 receptors within the dorsal striatum, an alteration that downstream reduces intracellular cyclic AMP (cAMP) signaling pathways |
| Dopamine Transporter T356M mutation kinetics in autism | highly conserved de novo mutation swaps threonine for methionine (T356M) in the DAT protein across species, severely impairing dopamine transport kinetics & inducing profound hyperactivity, even during nocturnal periods |
| Peripheral versus central serotonin paradox in autism | Peripheral hyperserotonemia (elevated blood serum 5-HT from platelets & enterochromaffin cells) but decreased serotonin levels & reduced 5-HT2A receptor binding in the brain. Tryptophan is depleted & SSRIs have little theraputic benefit |
| SERT Gly56Ala variant effects in autism | Gain-of-function mutation in SERT elevates blood serotonin, slows raphe nucleus firing, & directly alters social communication & interaction behaviors in vivo |
| Parental age & non-genetic autism risk factors | Advanced maternal age, C-section, & a large age gap between parents dramatically increase likelihood of ASD. Mitochondrial dysfunction, inflammation, oxidative stress, & environmental toxins |
| Gut dysbiosis & intestinal permeability in ASD | Altered gut microbiota triggers neuroinflammation via inflammatory cytokines released into the bloodstream. Dysbiosis is associated with a highly permeable ("leaky") GI tract, affecting local monoamine & neuropeptide production |
| Maternal immune activation & Bacteroides fragilis | Inducing maternal immune activation in pregnant mice alters offspring microbiota, leading to anxious phenotype. Oral treatment of offspring with the bacterial strain Bacteroides fragilis reverses this behavioral phenotype |
| Non-medication autism therapy | If delivered early enough can help improve later life symptoms by promoting Theory of Mind & encouraging socialising |
| Autism common comorbidities | GI disturbances (~50%), sleep disturbances, motor deficits, ADHD, mood disorders, anxiety, depression, OCD |
| Difficulties with biological diagnosis of autism | No specific common microscopic or macroscopic neuropathologies, brain region, or biomarkers. Possible to indicate with eye-tracking, autistic people's eyes linger for less time on the face |
| Genetic predisposition stats | Only 3% are single-gene mandelian inheritance. Some have CNVs, 10% have spontaneous de-novo mutations, ~80% are unexplained or have too many factors. Siblings have ~20% concordance but 60-90% in identical twins |